In Abbott’s bid to halt purchase of Alere, the MAC makes a comeback

Steven Davidoff Solomon writes for The New York Times, Dec. 7, 2016

Certainly the question when a target is faced with a MAC is, why take the risk? Why engage in litigation where you are basically arguing about how bad the company is? In most cases this dynamic works toward settlement.